IP Verse

Compositions And Methods For Increasing The Serum Half-Life Of A Therapeutic Agent Targeting Complement C5 - EP2978451

The patent EP2978451 was granted to Alexion Pharmaceuticals on Nov 27, 2019. The application was originally filed on Mar 28, 2014 under application number EP14722916A. The patent is currently recorded with a legal status of "Revoked".

EP2978451

ALEXION PHARMACEUTICALS
Application Number
EP14722916A
Filing Date
Mar 28, 2014
Status
Revoked
May 5, 2023
Grant Date
Nov 27, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ALNYLAM PHARMACEUTICALSAug 27, 2020HOFFMANN EITLEADMISSIBLE
REGENERON PHARMACEUTICALSAug 27, 2020CARPMAELS & RANSFORDADMISSIBLE

Patent Citations (51) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0413622
DESCRIPTIONEP0430539
DESCRIPTIONEP0488401
DESCRIPTIONUS2003143204
DESCRIPTIONUS2003166282
DESCRIPTIONUS2003224432
DESCRIPTIONUS2004038278
DESCRIPTIONUS2005271660
DESCRIPTIONUS2007048248
DESCRIPTIONUS2007172483
DESCRIPTIONUS2008241223
DESCRIPTIONUS2009110679
DESCRIPTIONUS2011111406
DESCRIPTIONUS3710795
DESCRIPTIONUS4863457
DESCRIPTIONUS4987071
DESCRIPTIONUS5093246
DESCRIPTIONUS5116742
DESCRIPTIONUS5308341
DESCRIPTIONUS5501856
DESCRIPTIONUS6146361
DESCRIPTIONUS6192891
DESCRIPTIONUS6200296
DESCRIPTIONUS6277099
DESCRIPTIONUS6277375
DESCRIPTIONUS6302855
DESCRIPTIONUS6355245
DESCRIPTIONUS7556615
DESCRIPTIONWO0177137
DESCRIPTIONWO0178693
DESCRIPTIONWO2004007553
DESCRIPTIONWO2004024156
DESCRIPTIONWO2004026380
DESCRIPTIONWO2005074607
DESCRIPTIONWO2010015608
DESCRIPTIONWO2010054403
DESCRIPTIONWO2010136311
DESCRIPTIONWO2010151526
DESCRIPTIONWO9315199
DESCRIPTIONWO9315200
DESCRIPTIONWO9734631
DESCRIPTIONWO9823289
INTERNATIONAL-SEARCH-REPORTWO2007103549
INTERNATIONAL-SEARCH-REPORTWO2011109338
OPPOSITIONEP2970974
OPPOSITIONWO2007103549
OPPOSITIONWO2007106585
OPPOSITIONWO2010054403
OPPOSITIONWO2010151526
OPPOSITIONWO2011109338
OPPOSITIONWO2014160129

Non-Patent Literature (NPL) Citations (14) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- C5 siRNA (h): sc-42848, (20120000), page 1, URL: http://datasheets.scbt.com/sc-42848.pdf, (20140704), XP055126933
OPPOSITION- CHENG LING-LI et al., "Effect of C5 siRNA silencing receptor C5 on myocardial ischemia injury in rats", Journal of Southern Medical University, (20100000), vol. 30, pages 1486 - 1488, XP008170341
OPPOSITION- HERPER M, "The world's most expensive drugs", Forbes, (20100222), XP055751228
OPPOSITION- KELLY RJ et al., "Successful management of intravascular breakthrough hemolysis on standard dose eculizumab therapy in PNH", Blood, (20080000), vol. 112, no. 11, page 1181
OPPOSITION- "Soliris 300 mg concentrate for solution for infusion", Summary of Product Characteristics, (20121008), XP055751177
OPPOSITION- MARTEL C et al., "Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial", Am Heart J., (20120000), vol. 164, no. 1, doi:10.1016/j.ahj.2012.04.007, pages 43 - 51, XP028405489
OPPOSITION- RICKLIN D et al., "Complement-targeted therapeutics", Nat Biotechnol., (20070000), vol. 25, no. 11, doi:10.1038/NBT1342, pages 1265 - 1275, XP002546813
OPPOSITION- ROTHER RP et al., "Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria", Nature Biotechnology, (20070000), vol. 25, doi:10.1038/nbt1344, pages 1256 - 1264, XP002553743
OPPOSITION- FOUGEROLLES et al., "Interfering with disease: a progress report on siRNA-based therapeutics", Nature Reviews Drug Discovery, (20070000), vol. 6, doi:10.1038/nrd2310, pages 443 - 53, XP037065522
OPPOSITION- HILLMEN P et al., "Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria", N Engl J Med., (20040000), vol. 350, pages 552 - 559, XP009057948
OPPOSITION- HOLERS, "The spectrum of complement alternative pathway-mediated diseases", Immunological Reviews, (20080000), vol. 223, doi:10.1111/j.1600-065X.2008.00641.x, pages 300 - 316, XP002553744
OPPOSITION- TANG, K et al., "Protective effect of C5 shRNA on myocardial ischemia- reperfusion injury in rats", Canadian Journal of Physiology and Pharmacology, (20120000), vol. 90, no. 10, doi:10.1139/y2012-114, pages 1394 - 1402, XP008170044
OPPOSITION- BRODSKY RA et al., "Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria", Blood, (20080000), vol. 111, doi:10.1182/blood-2007-06-094136, pages 1840 - 1847, XP055228630
OPPOSITION- KELLY et al., "The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab", Therapeutics and Clinical Risk Management, (20090000), vol. 5, pages 911 - 921, XP055751187

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents